Do You Like Cash? Consider DaVita Stock

DVAYTD+37.6%SPYYTD+5.8%XLVYTD+16.1%
Analyze DVA →

Today’s big story: Will 2027 Be A 2022 Repeat For Stocks?

On November 19, 2026, DaVita (DVA) stock closed 35.1% below its July 29 high. At that price, the shares offer buyers an unusual amount of cash. Over the past 12 months, the company’s free cash flow equaled 13.0% of its market value, compared to 4.4% for the median S&P 500 company. A yield that high usually marks a business on sale or one expected to shrink. So what kind of business is behind DaVita’s cash?

A 35.1% drop since July is a hard fall to sit through for anyone holding DaVita. If the stock is a big share of your savings, it helps to know how you could limit the next fall or sell without a heavy tax bill. Our partner advisory firm will take your question on a free 30-minute call, by phone or video, with no obligation. Book a free call.

Image from Pixabay

A Growing Dialysis Business Produces DaVita’s Cash

U.S. dialysis generated most of DaVita’s revenue in fiscal 2025, bringing in $11.8 billion. Shareholders own a slice of the cash this business produces, regardless of whether the company pays it out. Stock prices tend to follow when the market recognizes that cash, particularly when the cash is growing.

Total revenue rose 6.4% to $14.2 billion over the 12 months to September 30, 2026. The operating margin was 15.2%, climbing from 14.6% a year earlier. Over those 12 months, DaVita directed 30.8% of its cash from operations toward capital spending.

Measured a year apart, the cash has held level. DaVita recorded $1.29 billion in free cash flow over the 12 months to September 30, 2026, matching the figure from a year earlier. Three years earlier, free cash flow stood at $1.31 billion.

DaVita also carries heavy debt. On September 30, 2026, net debt, calculated as what the company owes minus its cash, stood at $12.8 billion. That debt load compares against a market value of $9.98 billion.

DaVita Is Adding Patients, But Slowly

On the October 29 call, management said treatment volume grew 1.2% in the third quarter of 2026 from a year earlier. Revenue per treatment rose about 1.1%, as lower pay for phosphate binders and a smaller share of commercial patients partly offset normal rate increases.

Under Medicare’s final rule for 2027, the headline rate increase for large dialysis companies is 3.5%. Management said 3.1% of that rate applies only to the first quarter and should come down sharply after it. The rest of the rate holds all year. So management estimates DaVita’s net gain for 2027 at 1.5% to 2%. Each 1% change in Medicare rates is worth about $30 million a year to DaVita.

Management’s answer is expanded HD, a new form of dialysis compatible with DaVita’s existing machines. Management expects the treatment to reduce mortality and lift volume growth from the second half of 2028. By 2029, DaVita’s goal is volume growth of 2% or more.

Management did not cut its 2026 forecasts on that call. The company kept its free cash flow forecast and narrowed its adjusted operating income range. That makes the pressure look like a slow stretch rather than a shrinking business.

Cash Fell In DaVita’s Latest Quarter

Based on reported figures, DaVita’s free cash flow fell to $0.36 billion in the third quarter of 2026, down from $0.68 billion a year earlier. That one quarter pulled the 12-month total down to $1.29 billion, from $1.61 billion three months earlier. Management still expects $1 billion to $1.25 billion in free cash flow for 2026, on its own measure. That is below the $1.29 billion behind the 13.0% yield.

For now, DaVita can cover the interest on its debt. Its operating income was 3.6 times its interest expense over the past 12 months. Management said it has capped the rate on about 80% of its floating-rate debt for three years.

DaVita is expected to report in February 2027. That report will show how much cash the company produced over all of 2026.

A business can generate plenty of cash and still experience harsh stock swings. Many investors find those swings easier to live with when they earn steady income from holdings that tend to fall less.

More Income. Smaller Drops.

Is your portfolio paying you enough? The Trefis Income Solution holds 50 dividend stocks yielding about 3x the S&P 500, each with at least 10 straight years of dividends. It lost less than the S&P 500 in all 9 big selloffs since 2018. Why not choose a better approach?

See The Income Solution

Spot an error or want more like this? Tell us in 10 seconds.